Gsk (GLAXF) Total Liabilities (2009 - 2026)

Gsk's Total Liabilities history runs 18 years deep, the most recent figure standing at -$61.3 billion for Q1 2026.

• In Q1 2026, Total Liabilities fell 3.39% year-over-year to -$61.3 billion; the TTM figure through Mar 2026 stood at -$61.3 billion (down 3.39% YoY), while the FY2025 annual figure was -$59.5 billion, down 200.45% from the prior year.
• Total Liabilities was -$61.3 billion for Q1 2026 at Gsk, down from -$60.1 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $59.5 billion in Q4 2024 to a low of -$83.6 billion in Q2 2022.
• Historically, Total Liabilities has averaged -$37.9 billion across 5 years, with a median of -$59.2 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities surged 69.01% in 2022, then sank 200.92% in 2025.
• A 5-year view of Total Liabilities shows it stood at $58.7 billion in 2022, then decreased by 2.3% to $57.4 billion in 2023, then rose by 3.79% to $59.5 billion in 2024, then sank by 200.92% to -$60.1 billion in 2025, then fell by 1.99% to -$61.3 billion in 2026.
• The last three Total Liabilities figures came in at -$61.3 billion (Q1 2026), -$60.1 billion (Q4 2025), and -$61.5 billion (Q3 2025), per Business Quant data.